| Second-line rituximab–bendamustine versus rituximab–gemcitabine–oxaliplatin in diffuse large B-cell lymphoma in the real world R Ionescu-Ittu, A Shang, NV Velde, A Guerin, Y Lin, L Shi, S Shi, N Qayum Journal of Comparative Effectiveness Research 8 (13), 1067-1075, 2019 | 14 | 2019 |
| Analysis on geographic variations in hospital deaths and endovascular therapy in ischaemic stroke patients: an observational cross-sectional study in China H Chen, L Shi, N Wang, Y Han, Y Lin, M Dai, H Liu, X Dong, M Xue, H Xu BMJ open 9 (6), e029079, 2019 | 14 | 2019 |
| Using modern risk engines and machine learning/artificial intelligence to predict diabetes complications: A focus on the BRAVO model H Shao, L Shi, Y Lin, V Fonseca Journal of Diabetes and its Complications 36 (11), 108316, 2022 | 13 | 2022 |
| Effects of medicaid expansion on poverty disparities in health insurance coverage Y Lin, A Monnette, L Shi International Journal for Equity in Health 20, 1-11, 2021 | 13 | 2021 |
| Predicting incident heart failure among patients with type 2 diabetes mellitus: The DM‐CURE risk score Y Lin, H Shao, L Shi, AH Anderson, V Fonseca Diabetes, Obesity and Metabolism 24 (11), 2203-2211, 2022 | 7 | 2022 |
| The effect of proton pump inhibitor use on the course of kidney function in patients with chronic kidney disease stages G3a to G4 S Giusti, Y Lin, F Sogbetun, N Nakhoul, S Liu, L Shi, V Batuman The American Journal of the Medical Sciences 362 (5), 453-461, 2021 | 7 | 2021 |
| Optimizing treatment goals for long-term health outcomes among patients with type 2 diabetes mellitus Q Shi, Y Lin, VA Fonseca, L Shi BMJ Open Diabetes Research and Care 9 (1), e002396, 2021 | 5 | 2021 |
| A prediction model on incident ESKD among individuals with T2D and CKD Y Lin, H Shao, V Fonseca, AH Anderson, V Batuman, L Shi Journal of Diabetes and its Complications 37 (4), 108450, 2023 | 3 | 2023 |
| A prediction model of CKD progression among individuals with type 2 diabetes in the United States Y Lin, H Shao, V Fonseca, AH Anderson, V Batuman, L Shi Journal of Diabetes and its Complications 37 (3), 108413, 2023 | 3 | 2023 |
| A machine learning approach identifies modulators of heart failure hospitalization prevention among patients with type 2 diabetes: a revisit to the ACCORD trial H Kianmehr, J Guo, Y Lin, J Luo, W Cushman, L Shi, V Fonseca, H Shao Journal of Diabetes and its Complications 36 (9), 108287, 2022 | 3 | 2022 |
| Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes Y Lin, H Shao, V Fonseca, L Shi Journal of Diabetes 15 (3), 215-223, 2023 | 2 | 2023 |
| Effect of continuity of care on emergency department and hospital visits for obesity-associated chronic conditions: a federated cohort meta-analysis S Surbhi, M Chen, SA Shuvo, E Price-Haywood, L Shi, J Mann, Y Lin, ... Journal of the National Medical Association 114 (5), 525-533, 2022 | 2 | 2022 |
| Comparable Overall Survival with Rituximab-Bendamustine (R-Benda) and Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) When Used As Second-Line (2L) Treatment for Diffuse Large B … R Ionescu-Ittu, A Shang, N Vander Velde, A Guérin, Y Lin, L Shi, S Shi, ... Blood 132, 1711, 2018 | 2 | 2018 |
| Geographical variations in endovascular therapy and hospital mortality in patients with stroke in China: a nationwide cross-sectional analysis from tertiary hospitals H Chen, L Shi, N Wang, Y Han, Y Lin, X Dong, Y Cai, H Liu, M Xue, H Xu The Lancet 392, S26, 2018 | 2 | 2018 |
| 2000 年-2014 年全球新兴卫生技术发展态势分析 周萍， 林亦璐， 夏志远， 陈英耀， 张致远 中国卫生质量管理 22 (6), 99-101, 2015 | 2 | 2015 |
| 132-OR: Trends in Total Payments, Net Payments, and Rebates for a 30-Day Supply of Glucose-Lowering Drugs (GLDs) from 2010–2017 YAO Ding, L Shi, Y Lin, HUI Shao Diabetes 71 (Supplement_1), 2022 | 1 | 2022 |
| Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer DJ George, N Agarwal, K Ramaswamy, Z Klaassen, RL Bitting, D Russell, ... Prostate Cancer and Prostatic Diseases, 1-11, 2024 | | 2024 |
| Some patients with type 2 diabetes may benefit from intensive glycaemic and blood pressure control: A post‐hoc machine learning analysis of ACCORD trial data T Jiao, H Kianmehr, Y Lin, P Li, N Singh Ospina, HK Ghayee, M Ruzieh, ... Diabetes, Obesity and Metabolism, 2024 | | 2024 |
| Racial/ethnic disparities in the effectiveness of atezolizumab plus bevacizumab (A+ B) vs. tyrosine kinase inhibitors (TKIs) among veterans with unresectable hepatocellular … DE Kaplan, A Tan, C Xiang, F Mu, S Hernandez, S Ogale, M Sundar, ... Journal of Clinical Oncology 42 (3_suppl), 448-448, 2024 | | 2024 |
| Comparing first-line (1L) atezolizumab plus bevacizumab (A+ B) to lenvatinib (L) or sorafenib (S) in patients with unresectable hepatocellular carcinoma (uHCC): Findings from … DE Kaplan, A Tan, C Xiang, F Mu, S Ogale, S Hernandez, J Li, Y Lin, ... Journal of Clinical Oncology 42 (3_suppl), 446-446, 2024 | | 2024 |
